Home › Funds › Avalon Trust Co › PPH
Avalon Trust Co position in PPH
VANECK PHARMACEUTICAL ETF
Avalon Trust Co reported holding 254,155 shares of PPH (VANECK PHARMACEUTICAL ETF) in its Q3 2026 13F filing — a position valued at US$27.8M, representing 1.74% of its reported portfolio and ranking #13 among its reported holdings. Avalon Trust Co has disclosed PPH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Avalon Trust Co's PPH position evolved
Avalon Trust Co first disclosed a stake in PPH in Q3 2023 at 287,575 shares (US$23.0M). The position peaked in Q2 2026 at 263,830 shares, worth US$28.8M. Across 13 filings, Avalon Trust Co increased the stake 0 time(s), trimmed it 7 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 254,155 shares valued at US$27.8M — a reduction of -9,675 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 287.57K | $22.97M | New |
| Q4 2023 | 285.38K | $23.22M | Reduce |
| Q1 2024 | 284.88K | $25.84M | Hold |
| Q2 2024 | 284.98K | $26.07M | Hold |
| Q3 2024 | 282.80K | $26.87M | Reduce |
| Q4 2024 | 282.79K | $24.40M | Hold |
| Q1 2025 | 283.69K | $25.85M | Hold |
| Q2 2025 | 280.48K | $24.67M | Reduce |
| Q3 2025 | 275.40K | $24.89M | Reduce |
| Q4 2025 | 267.85K | $27.63M | Reduce |
| Q1 2026 | 267.70K | $27.81M | Hold |
| Q2 2026 | 263.83K | $28.85M | Reduce |
| Q3 2026 | 254.16K | $27.82M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PPH and 13F data
PPH (VANECK PHARMACEUTICAL ETF) is a company whose sector is not yet classified in our data. 20 other funds we track also report a position in PPH — the largest reported positions include J.Safra Asset Management Corp (US$35.9M), ADAMSBROWN WEALTH CONSULTANTS LLC (US$11.1M), Rye Brook Capital LLC (US$7.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PPH
- J.Safra Asset Management Corp 328.31K sh · $35.94M · Q3 2026
- ADAMSBROWN WEALTH CONSULTANTS LLC 101.70K sh · $11.13M · Q3 2026
- Rye Brook Capital LLC 70.25K sh · $7.69M · Q3 2026
- WT Wealth Management 47.80K sh · $5.23M · Q3 2026
- Fortis Group Advisors, LLC 31.59K sh · $3.77M · Q3 2026
- Fluent Financial, LLC 26.90K sh · $2.94M · Q3 2026
More on Avalon Trust Co
FAQ
How long has Avalon Trust Co held PPH?
Avalon Trust Co has disclosed PPH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Avalon Trust Co's current position in PPH?
As of Q3 2026, Avalon Trust Co holds 254.16K shares of PPH (VANECK PHARMACEUTICAL ETF), valued at $27.82M, representing 1.74% of its reported portfolio and ranking #13.
Has Avalon Trust Co been buying or selling PPH?
In the latest 13F filing (Q3 2026), Avalon Trust Co reduced its position in PPH. The position peaked in Q2 2026 at 263.83K shares.
Which other funds hold PPH?
Other major institutional holders of PPH include J.Safra Asset Management Corp, ADAMSBROWN WEALTH CONSULTANTS LLC, Rye Brook Capital LLC, among 20 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.